Leiden, The Netherlands, May 15, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) has announced that its Annual General Meeting of Shareholders (AGM) will be held at the Pieterskerk in Leiden on June 2, 2006, commencing at 14.00 CET.

 

All documentation relating to the AGM, including Crucell's 2005 Annual Report and the meeting's agenda, can be found in the Investor section of the Crucell website (www.crucell.com). A live video webcast of the AGM will be available via the homepage of the Crucell website, and will be available for replay following the event.

 

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes vaccines against hepatitis B and virosomal influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, elsewhere in Europe, and in Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

 

Click below for a PDF version of this press release: